What Happened?
New York, NY-based Mustang Bio Promoted Knut Niss as Chief Technology Officer
Date of management change: March 15, 2018
New York, NY-based Mustang Bio Promoted Knut Niss as Chief Technology Officer
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
Knut Niss is Chief Technology Officer at Egenesis Bio. Previously, Knut held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Buonauro Mark, Prokter Gregory, Filbey David, Distefano Glen, Schaffer Greg, Chapman Richard, Balasubramanian Ram, Maher Andy, Mullins Mathias, Redding Brandon, Basso Gillian
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.